Search Results

Strategic Investments in the EU and US strengthen Vetter’s Global Footprint • Building permit application for German site submitted • Construction start is scheduled for the 2nd quarter 2026, with operational readiness in 2031 • Expansions in the US and Europe are included in a €1.5 billion investment plan

In its rejection letter, the FDA flagged problems at a third-party fill-finish site owned by Novo Nordisk. Issues at this site have previously been investigated by the regulator.

• The capacity expansion in Bubendorf reached another important milestone with the inspection of Building K. The announced start-up is proceeding according to plan. • In Vista, CA, Bachem acquired a property adjacent to its existing facility. The acquisition will enable a future capacity expansion at the Vista site, thereby strengthening Bachem’s presence in the US market.

Follow along as BioSpace tracks job cuts and restructuring initiatives.

Pharmaceutical service provider expands its footprint in the greater Chicago area · Production site expected to be ready for media fill by the end of 2029 · Modern site with holistic approach for state-of-the-art manufacturing operations · Fulfills the requirements for increased capacity in early clinical filling